缅北禁地

Personal Summary

From basic science research, I have moved my research interest focus to the next stage to facilitate gaining evidence to change clinical practice as quickly as possible. I primarily work with NIHR portfolio clinical trial studies.

Qualifications

 PGCert 2015 Clinical Research, 缅北禁地, UK

 PhD 2006 Molecular Cancer Biology, 缅北禁地, UK

 BSc 1999 (Hons) Biochemistry, University of Sussex, UK

Areas of expertise

Clinical Trial Management (NIHR funded)

Translational Clinical Trial Management (assay development, clinical and biological validation and clinical utility)

Biomarker Discovery (companion/predictive in terms of treatment/disease outcomes, personalised medicine)

Urology based research specialising in molecular biology of hormone escape in Cancer

Previous Positions

2006-2020 Research Associate - Urological Cancer, Northern Institute for Cancer Research, 缅北禁地, UK

2002- 2005 BBSRC (GSK Case) PhD Student - Institute for Cell & Molecular Biosciences, 缅北禁地, UK

2001-2002 Research Assistant - Dept. of Fetal Medicine, Birmingham Women's Hospital, UK

1999-2001 Graduate Pharmaceutical Scientific Researcher - Roche, Welwyn Garden City, UK

1997-1998 Industrial Studentship Placement - Home Office Forensic Science Service, Birmingham, UK

Membership/Committees

UK CRC registered Clinical Trials Units Network

UK TMN Trial Managers Network

UK NCRI Clinical Trials Pathology Advisory Group (CT-PAG)

Faculty of Medical Science 缅北禁地 Ethics committee member

Current Studies

1) NIHR HTA ASCEnD (Aripiprazole/sertraline combination: clinical and cost-effectiveness in comparison with quetiapine for the treatment of bipolar depression). Pragmatic, Open label, Randomised controlled trial with 9 month internal pilot phase. ISRCTN: 63917405.

Previous Studies

1) NIHR HTA CONFORM-OH (Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension: A Randomised Controlled Trial). Pragmatic, open label, randomised, prospective, superiority, multi-arm, multi-stage clinical trial with a 10-month internal pilot, phase IV. ISRCTN: 87213295.

2) NIHR HTA PREMISE (Prostate Resection versus Minimally Invasive Surgery Evaluation Trial). Multi-arm, multi-centre, non-inferiority randomised controlled trial, with six-month internal pilot. ness of three minimally invasive treatments (MITS) compared to transurethral resection of prostate (TURP) for treatment of bladder outlet obstruction (BOO) due to enlarged prostate). ISRCTN: 50571778 

3) NIHR HTA NAIROS surgery ENT intervention trial (Nasal AIRway Obstruction Study). Multi-site, pragmatic, randomised phase III trial: ISRCTN: 16168569.

4) Lead applicant for NIHR RfPB VARIANT advanced prostate cancer treatment biomarker trial (multi-site, biomarker guided, randomised feasibility funder reference: PB-PG-0816-20043).

5) Lead on translational arm (PHOTO-T) for HTA NIHR bladder cancer surgery intervention PHOTO trial (multi-site, pragmatic, randomised controlled phase III trial: ISRCTN 84013636). 

6) Commercial (Sanofi) advanced prostate cancer chemotherapy treatment response trial (single-site, pragmatic, observational trial CSP 102842).

Previous Funding 

Clinical Trials:

NIHR RfPB feasibility study (The Prostate Cancer Androgen Receptor Splice Variant 7 Biomarker Trial (The VARIANT trial) - A multicentre feasibility study of biomarker-guided personalised treatment in advanced prostate cancer - £276,230.00) awarded to Dr. E. L. Clark/ Mr R Heer (June 2018 - Sept 2020).

Basic Science:

PCUK PhD post (Characterising novel phosphatase enzymes important in regulating androgen receptor function in the progression of castrate resistant prostate cancer - £100.3K) awarded to Dr. E. L. Clark/Prof. C. N. Robson (Sept 2013-Sept 2016) 

JGWP technical support post (Assessing the role of RNA helicase p68 (Ddx5) in the deregulation of microRNAs and progression of Prostate Cancer - £52K) awarded to Dr. E. L. Clark/Prof. C. N. Robson (May 2012-May 2013)

Prostate Action project grant (Assessing RNA helicase p68 (Ddx5) as a biomarker in the deregulation of microRNAs in Prostate Cancer - £99,987) awarded to Dr. E. L. Clark/Prof. C. N. Robson (Jan 2012-Oct 2013)

PCRF project grant (Pharmacological perturbation of p68 - an important androgen receptor transcriptional co-regulator in prostate cancer - £99,941) awarded to Dr. E. L. Clark/Prof. C. N. Robson (Jan 2008- Dec 2011)

Industrial Relevance

Postgraduate Teaching

Past students:

Alex Lloyd MRes (2017 - 2018)

Emma Smith MRes (2016 - 2017)

Andrew Evans MRes (2015 - 2016)

James Grey PhD (2014 - 2016)

Victoria Shuttleworth UG (2011 - 2012)

Jake Clayton MRes (2010 - 2011)

Christiana Hadjimichael MRes (2007-2008)

• Articles

  • Carrie S, Fouweather T, Homer T, O'Hara J, Rousseau N, Rooshenas L, Bray A, Stocken DD, Ternent L, Rennie K, Clark E, Waugh N, Steel AJ, Dooley J, Drinnan M, Hamilton D, Lloyd K, Oluboyede Y, Wilson C, Gardiner Q, Kara N, Khwaja S, Leong SC, Maini S, Morrison J, Nix P, Wilson JA, Teare MD. . Health Technology Assessment 2024, 28(10).
  • Wyatt NJ, Watson H, Anderson CA, Kennedy NA, Raine T, Ahmad T, Allerton D, Bardgett M, Clark E, Clewes D, Martin CC, Doona M, Doyle JA, Frith K, Hancock H, Hart A, Hildreth V, Irving PM, Iqbal S, Kennedy C, King A, Lawrence S, Lees CW, Lees R, Letchford L, Liddle T, Lindsay JO, Maier RH, Mansfield JC, Marchesi JR, McGregor N, McIntyre RE, Ostermayer J, Osunnuyi T, Powell N, Prescott NJ, Satsangi J, Sharma S, Shrestha T, Speight A, Strickland M, Wason JMS, Whelan K, Wood R, Young GR, Zhang X, Parkes M, Stewart CJ, Jostins-Dean L, Lamb CA. . BMJ Open 2024, 14(4).
  • Gravestock P, Clark E, Morton M, Sharma S, Fisher H, Walker J, Wood R, Hancock H, Waugh N, Cooper A, Maier R, Marshall J, Chandler R, Bahl A, Crabb S, Jain S, Pedley I, Jones R, Staffurth J, Heer R. . NIHR Open Research 2023, 2, 49.
  • Yu G, Rice S, Heer R, Lewis R, Vadiveloo T, Mariappan P, Penegar S, Clark E, Tandogdu Z, Hall E, Vale L. . European Urology Open Science 2023, 53, 67-77.
  • Carrie S, O'Hara J, Fouweather T, Homer T, Rousseau N, Rooshenas L, Bray A, Stocken DD, Ternent L, Rennie K, Clark E, Waugh N, Steel AJ, Dooley J, Drinnan M, Hamilton D, Lloyd K, Oluboyede Y, Wilson C, Gardiner Q, Kara N, Khwaja S, Leong SC, Maini S, Morrison J, Nix P, Wilson JA, Teare MD. . BMJ 2023, 383, e075445.
  • Clark E, Morton M, Sharma S, Fisher H, Howel D, Walker J, Wood R, Hancock H, Maier R, Marshall J, Bahl A, Crabb S, Jain S, Pedley I, Jones R, Staffurth J, Heer R. . BMJ Open 2019, 9(12), e034708.
  • Tandogdu Z, Lewis R, Duncan A, Penegar S, McDonald A, Vale L, Shen J, Kelly JD, Pickard R, N Dow J, Ramsay C, Mostafid H, Mariappan P, Nabi G, Creswell J, Lazarowicz H, McGrath J, Taylor E, Clark E, Maclennan G, Norrie J, Hall E, Heer R. . BMJ Open 2019, 9(9), e022268.
  • Grey J, Jones D, Wilson L, Nakjang S, Clayton J, Temperley R, Clark E, Gaughan L, Robson C. . Oncotarget 2018, 9(3), 3922-3935.
  • Clark EL, Hadjimichael C, Temperley R, Barnard A, Fuller-Pace FV, Robson CN. . PLoS One 2013, 8(1), e54150.
  • Rajan P, Dalgliesh C, Bourgeois CF, Heiner M, Emami K, Clark EL, Bindereif A, Stevenin J, Robson CN, Leung HY, Elliott DJ. . BMC Cell Biology 2009, 10(1), 82.
  • Clark EL, Coulson AC, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, Fuller-Pace FV, Robson CN. . Cancer Research 2008, 68(19), 7938-7946.
  • Clark EL, Fuller-Pace FV, Elliott DJ, Robson CN. . Biochemical Society Transactions 2008, 36(3), 546-547.
  • Kilby MD, Barber K, Hobbs E, Franklyn JA. . Placenta 2005, 26(2-3), 105-113.
  • Chan S, Kachilele S, Hobbs E, Bulmer JN, Boelaert K, McCabe C, Driver P, Bradwell A, Kester M, Visser T, Franklyn J, Kilby M. . Journal of Clinical Endocrinology and Metabolism 2003, 88(9), 4488-4495.

• Authored Book

  • Clark EL. . 缅北禁地 upon Tyne: University of 缅北禁地 upon Tyne, 2006.

• Conference Proceedings (inc. Abstract)

  • McComb CM, Clark EL, Padget K, Harvey J, Morris NJ, Austin CA. . In: 30th Annual Meeting of the United Kingdom Environmental Mutagen Society. 2007, University of Cardiff, UK: Mutagenesis: Oxford University Press.